A Comprehensive Review on the Pharmacokinetics of Antibiotics in Interstitial Fluid Spaces in Humans: Implications on Dosing and Clinical Pharmacokinetic Monitoring

被引:42
|
作者
Kiang, Tony K. L. [1 ]
Haefeli, Urs O. [1 ]
Ensom, Mary H. H. [1 ,2 ]
机构
[1] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
[2] Childrens & Womens Hlth Ctr British Columbia, Dept Pharm 0B7, Vancouver, BC V6H 3N1, Canada
基金
加拿大自然科学与工程研究理事会; 加拿大健康研究院;
关键词
SUBCUTANEOUS ADIPOSE-TISSUE; TARGET SITE CONCENTRATIONS; CRITICALLY-ILL PATIENTS; IN-VIVO MICRODIALYSIS; SOFT-TISSUE; HEALTHY-VOLUNTEERS; DIABETIC-PATIENTS; INTRACELLULAR CONCENTRATIONS; ANTIMICROBIAL ACTIVITY; SKELETAL-MUSCLE;
D O I
10.1007/s40262-014-0152-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of the current review was to provide an updated and comprehensive summary on pharmacokinetic data describing the distribution of antimicrobials into interstitial fluid (ISF) by comparing drug concentration versus time profiles between ISF and blood/plasma in healthy individuals and/or diseased populations. An extensive literature search identified 55 studies detailing 87 individual comparisons. For each antibiotic (anti-bacterial) (or antibiotic class), we comment on dosing implications based on tissue ISF distribution characteristics and determine the suitability of conducting clinical pharmacokinetic monitoring (CPM) using a previously published scoring algorithm. Using piperacillin as an example, there is evidence supporting different degrees of drug penetration into the ISF of different tissues. A higher dose of piperacillin may be required to achieve an adequate ISF concentration in soft tissue infections. To achieve these higher doses, alternative administration regimens such as intravenous infusions may be utilized. Data also suggest that piperacillin can be categorized as a 'likely suitable' agent for CPM in ISF. Regression analyses of data from the published studies, including protein binding, molecular weight, and predicted partition coefficient (using XlogP3) as dependent variables, indicated that protein binding was the only significant predictor for the extent of drug distribution as determined by ratios of the area under the concentration-time curve between muscle ISF/total plasma (R-2 = 0.65, p < 0.001) and adipose ISF/total plasma (R-2 = 0.48, p < 0.004). Although recurrent limitations (i.e., small sample size, lack of statistical comparisons, lack of steady-state conditions, high individual variability) were identified in many studies, these data are still valuable and allowed us to generate general dosing guidelines and assess the suitability of using ISF for CPM.
引用
收藏
页码:695 / 730
页数:36
相关论文
共 8 条
  • [1] A Comprehensive Review on the Pharmacokinetics of Antibiotics in Interstitial Fluid Spaces in Humans: Implications on Dosing and Clinical Pharmacokinetic Monitoring
    Tony K. L. Kiang
    Urs O. Häfeli
    Mary H. H. Ensom
    Clinical Pharmacokinetics, 2014, 53 : 695 - 730
  • [2] A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans
    Tony K. L. Kiang
    Mary H. H. Ensom
    Clinical Pharmacokinetics, 2016, 55 : 313 - 358
  • [3] A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans
    Kiang, Tony K. L.
    Ensom, Mary H. H.
    CLINICAL PHARMACOKINETICS, 2016, 55 (03) : 313 - 358
  • [4] Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses
    Illamola, Silvia M.
    Sherwin, Catherine M.
    van Hasselt, J. G. Coen
    CLINICAL PHARMACOKINETICS, 2018, 57 (10) : 1217 - 1228
  • [5] Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses
    Sílvia M. Illamola
    Catherine M. Sherwin
    J. G. Coen van Hasselt
    Clinical Pharmacokinetics, 2018, 57 : 1217 - 1228
  • [6] Mycophenolic Acid and Its Pharmacokinetic Drug-Drug Interactions in Humans: Review of the Evidence and Clinical Implications
    Benjanuwattra, Juthipong
    Pruksakorn, Dumnoensun
    Koonrungsesomboon, Nut
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (03): : 295 - 311
  • [7] Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics
    Rao, Gauri G.
    Konicki, Robyn
    Cattaneo, Dario
    Alffenaar, Jan-Willem
    Marriott, Deborah J. E.
    Neely, Michael
    THERAPEUTIC DRUG MONITORING, 2020, 42 (01) : 83 - 92
  • [8] Comment on "Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies" and "High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints"
    Kong, Leping
    Alffenaar, Jan-Willem C.
    Stocker, Sophie L.
    CLINICAL PHARMACOKINETICS, 2024, 63 (05) : 731 - 733